Galectin-3 Immunohistochemical Expression in Thyroid Neoplasms

Overview

Journal J Clin Diagn Res

Specialty General Medicine

Date 2015 Dec 18

PMID 26673516

Citations 16

Authors

B S Sumana

Sampangiram Shashidhar

A S Shivarudrappa

Affiliations

Soon will be listed here.

Abstract

Background: Galectin-3 has been implicated in the regulation of cellular growth, differentiation and malignant transformation in various organs including thyroid gland. It has been extensively studied as an immunohistochemical (IHC) marker in thyroid malignancy.

Aim: To evaluate the diagnostic role of Galectin-3 (Gal-3) in differentiating malignant from benign thyroid neoplasm.

Materials And Methods: In this observational study we evaluated Gal-3 expression in a spectrum of malignant (30) and benign (20) thyroid neoplasms. The final common diagnosis arrived at after histopathologic evaluation of H&E stained sections by two pathologist's was considered the gold standard. The malignant neoplasms included Papillary Thyroid Carcinoma (PTC), Follicular Thyroid Carcinoma (FTC), Medullary Thyroid Carcinoma (MTC), insular carcinoma, Anaplastic Thyroid Carcinoma (ATC), and metastatic carcinoma. The benign neoplasms included Follicular Adenoma (FA), Hurthle cell adenoma and hyalinizing trabecular adenoma. IHC staining for Gal-3 was performed for all neoplasms with the polymeric method using lyophilized mouse monoclonal antibody.

Statistical Analysis: Statistical analysis was done using 2x2 contingency table. Chi-square test with Yates correction was used to calculate p-value to ascertain statistical significance.

Results: Gal-3 expression was significantly higher in malignant thyroid neoplasms as compared to benign neoplasms (p<0.0001). Gal-3 expression in differentiating malignant from benign neoplasms was found to have sensitivity of 86%, specificity of 85%, positive predictive value of 89.66% and negative predictive value of 80.95%. However, no statistical significance was observed (p=0.4718) when comparing PTC and other malignant lesions in terms of Gal-3 expression. Gal- 3 expression in PTC was found to have sensitivity of 91.3%, specificity of 85%, positive predictive value of 87.5% and negative predictive value of 89.47%.

Conclusion: Diffuse and strong IHC staining for Gal-3 differentiates malignant from benign tumours. This marker can assist in the diagnosis of thyroid neoplasms with equivocal morphologic features. This study highlights the high sensitivity of Gal-3 for PTC.

Citing Articles

Current Trends in Biohumoral Screening for the Risk of Sudden Cardiac Death: A Systematic Review.

Isaila O, Moroianu L, Hostiuc S Medicina (Kaunas). 2024; 60(3).

PMID: 38541144 PMC: 10972295. DOI: 10.3390/medicina60030418.

Targeting Galectin 3 illuminates its contributions to the pathology of uterine serous carcinoma.

Matoba Y, Zarrella D, Pooladanda V, Azimi Mohammadabadi M, Kim E, Kumar S Br J Cancer. 2024; 130(9):1463-1476.

PMID: 38438589 PMC: 11058234. DOI: 10.1038/s41416-024-02621-x.

Immunomodulation exerted by galectins: a land of opportunity in rare cancers.

Diaz-Alvarez L, Lopez-Cortes G, Perez-Figueroa E Front Immunol. 2023; 14:1301025.

PMID: 38022609 PMC: 10663293. DOI: 10.3389/fimmu.2023.1301025.

Galectin-3's Complex Interactions in Pancreatic Ductal Adenocarcinoma: From Cellular Signaling to Therapeutic Potential.

Dimitrijevic Stojanovic M, Stojanovic B, Radosavljevic I, Kovacevic V, Jovanovic I, Stojanovic B Biomolecules. 2023; 13(10).

PMID: 37892182 PMC: 10605315. DOI: 10.3390/biom13101500.

Prognostic value of galectin-1 and galectin-3 expression in localized urothelial bladder cancer.

Zhu J, Livasy C, Donahue E, Symanowski J, Grigg C, Brown L Transl Androl Urol. 2023; 12(2):228-240.

PMID: 36915891 PMC: 10005997. DOI: 10.21037/tau-22-494.

References

Weber K, Shroyer K, Heinz D, Nawaz S, Said M, Haugen B . The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer. Am J Clin Pathol. 2004; 122(4):524-31. DOI: 10.1309/UUQT-E505-PTN5-QJ7M. View

Liu Y, Morreau H, Kievit J, Romijn J, Carrasco N, Smit J . Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of.... Eur J Endocrinol. 2008; 158(3):375-84. DOI: 10.1530/EJE-07-0492. View

Xu X, El-Naggar A, Lotan R . Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. Am J Pathol. 1995; 147(3):815-22. PMC: 1870977. View

Fernandez P, Merino M, Gomez M, Campo E, Medina T, Castronovo V . Galectin-3 and laminin expression in neoplastic and non-neoplastic thyroid tissue. J Pathol. 1997; 181(1):80-6. DOI: 10.1002/(SICI)1096-9896(199701)181:1<80::AID-PATH699>3.0.CO;2-E. View

Shimura T, Takenaka Y, Tsutsumi S, Hogan V, Kikuchi A, Raz A . Galectin-3, a novel binding partner of beta-catenin. Cancer Res. 2004; 64(18):6363-7. DOI: 10.1158/0008-5472.CAN-04-1816. View

Aiad H, Kandil M, Asaad N, El-Kased A, El-Goday S . Galectin-3 immunostaining in cytological and histopathological diagnosis of thyroid lesions. J Egypt Natl Canc Inst. 2009; 20(1):36-46. View

Cvejic D, Savin S, Petrovic I, Selemetjev S, Paunovic I, Tatic S . Galectin-3 and proliferating cell nuclear antigen (PCNA) expression in papillary thyroid carcinoma. Exp Oncol. 2005; 27(3):210-4. View

Gaffney R, Carney J, Sebo T, Erickson L, Volante M, Papotti M . Galectin-3 expression in hyalinizing trabecular tumors of the thyroid gland. Am J Surg Pathol. 2003; 27(4):494-8. DOI: 10.1097/00000478-200304000-00009. View

Bartolazzi A, Gasbarri A, Papotti M, Bussolati G, Lucante T, Khan A . Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet. 2001; 357(9269):1644-50. DOI: 10.1016/s0140-6736(00)04817-0. View

10.

Feilchenfeldt J, Totsch M, Sheu S, Robert J, Spiliopoulos A, Frilling A . Expression of galectin-3 in normal and malignant thyroid tissue by quantitative PCR and immunohistochemistry. Mod Pathol. 2003; 16(11):1117-23. DOI: 10.1097/01.MP.0000096047.99202.31. View

11.

Baloch Z, LiVolsi V . Follicular-patterned lesions of the thyroid: the bane of the pathologist. Am J Clin Pathol. 2002; 117(1):143-50. DOI: 10.1309/8VL9-ECXY-NVMX-2RQF. View

12.

Nangia-Makker P, Nakahara S, Hogan V, Raz A . Galectin-3 in apoptosis, a novel therapeutic target. J Bioenerg Biomembr. 2007; 39(1):79-84. PMC: 3616377. DOI: 10.1007/s10863-006-9063-9. View

13.

Hundahl S, FLEMING I, Fremgen A, Menck H . A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns]. Cancer. 1999; 83(12):2638-48. DOI: 10.1002/(sici)1097-0142(19981215)83:12<2638::aid-cncr31>3.0.co;2-1. View

14.

Elsheikh T, Asa S, Chan J, DeLellis R, Heffess C, LiVolsi V . Interobserver and intraobserver variation among experts in the diagnosis of thyroid follicular lesions with borderline nuclear features of papillary carcinoma. Am J Clin Pathol. 2008; 130(5):736-44. DOI: 10.1309/AJCPKP2QUVN4RCCP. View

15.

Lee Y, Lee J . Prognostic value of epidermal growth factor receptor, p53 and galectin-3 expression in papillary thyroid carcinoma. J Int Med Res. 2013; 41(3):825-34. DOI: 10.1177/0300060513477312. View

16.

Fischer S, Asa S . Application of immunohistochemistry to thyroid neoplasms. Arch Pathol Lab Med. 2008; 132(3):359-72. DOI: 10.5858/2008-132-359-AOITTN. View

17.

Herrmann M, LiVolsi V, Pasha T, Roberts S, Wojcik E, Baloch Z . Immunohistochemical expression of galectin-3 in benign and malignant thyroid lesions. Arch Pathol Lab Med. 2002; 126(6):710-3. DOI: 10.5858/2002-126-0710-IEOGIB. View

18.

Prasad M, Pellegata N, Huang Y, Nagaraja H, de la Chapelle A, Kloos R . Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol. 2004; 18(1):48-57. DOI: 10.1038/modpathol.3800235. View

19.

Chiu C, Strugnell S, Griffith O, Jones S, Gown A, Walker B . Diagnostic utility of galectin-3 in thyroid cancer. Am J Pathol. 2010; 176(5):2067-81. PMC: 2861072. DOI: 10.2353/ajpath.2010.090353. View

20.

Park Y, Kwak S, Kim D, Kim H, Choe G, Park D . Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules. J Korean Med Sci. 2007; 22(4):621-8. PMC: 2693809. DOI: 10.3346/jkms.2007.22.4.621. View